Yourresearch,
distilledweekly.
Skophos scans thousands of papers across PubMed, bioRxiv, and more — then delivers a curated, AI-scored digest every week. Stop missing what matters.
CRISPR-Cas9 lipid nanoparticle delivery achieves 94% efficiency in vivo
Zhang, M., Patel, R. et al. · MIT Koch Institute
Single-cell transcriptomics reveals tumor microenvironment remodeling
Dubois, A., Kim, S. et al. · Institut Curie
+ 23 more papers in your full digest
Sources covered
PubMed
NCBI / NLM
bioRxiv
Preprints — Biology
medRxiv
Preprints — Medicine
Europe PMC
Open Access
Semantic Scholar
AI-powered search
PubMed
NCBI / NLM
bioRxiv
Preprints — Biology
medRxiv
Preprints — Medicine
Europe PMC
Open Access
Semantic Scholar
AI-powered search
From the churn to clarity,
in three steps.
Build your research profile
Tell Skophos your field, keywords, favorite journals, and methodological interests. The more specific you are, the sharper your digest.
AI scans & scores the literature
Every week, our engine scans thousands of papers from PubMed, bioRxiv, medRxiv, and Europe PMC. Each paper is scored 0–100 against your profile — factoring in relevance, novelty, and methodological fit.
Receive your curated digest
On your chosen day, your digest lands in your inbox. Top papers with AI summaries, "why it matters" explanations tailored to your research, and direct links to the full text.
See exactly what you'll receive.
Here's a live preview of a Skophos digest. Toggle between the email and web versions.
CRISPR-Cas9 lipid nanoparticle delivery achieves 94% efficiency in vivo
Zhang, M., Patel, R., Hernandez, L. et al. · MIT Koch Institute
A novel LNP formulation enables systemic delivery of CRISPR-Cas9 complexes with unprecedented efficiency, achieving 94% gene editing efficiency in hepatocytes without detectable off-target effects.
Why it matters
Direct implication for gene therapy delivery vectors -- the pH-responsive mechanism could be adapted for your target tissue.
Phase III CHRYSALIS-2: Amivantamab plus lazertinib versus osimertinib in first-line EGFR-mutant NSCLC
Cho, B.C., Felip, E., Hayashi, H. et al. · Dana-Farber Cancer Institute
This phase III trial demonstrates superior progression-free survival (23.7 vs 16.6 months) for the amivantamab-lazertinib combination versus osimertinib monotherapy in previously untreated EGFR-mutant advanced NSCLC, establishing a new first-line standard.
Why it matters
First randomized evidence that bispecific antibody + TKI outperforms current standard of care — directly relevant for your NSCLC treatment protocols.
Single-cell transcriptomics reveals tumor microenvironment remodeling under anti-PD1 therapy
Dubois, A., Kim, S., Okonkwo, F. et al. · Institut Curie
High-resolution single-cell profiling of 47,000 tumor-infiltrating cells reveals a previously undescribed population of exhausted T cells that drives immunotherapy resistance via IL-35 secretion.
Why it matters
Challenges current assumptions about T cell exhaustion in immunotherapy models.
Deep learning model predicts protein-ligand binding affinity with sub-angstrom precision
Muller, T., Rashid, A., Chen, X. et al. · ETH Zurich
BindFormer achieves sub-angstrom RMSD in binding pose prediction and outperforms AutoDock Vina by 34% on the PDBbind benchmark.
Why it matters
Could significantly accelerate virtual screening pipelines -- the model weights are open-source.
Everything you need,
nothing you don't.
AI-powered relevance scoring
Each paper is scored 0–100 against your specific research profile. Rate articles to fine-tune your scores over time.
"Why it matters" explanations
Not just summaries — every paper comes with a personalized explanation of why it's relevant to your specific research.
Every major source, one digest
Skophos aggregates PubMed, bioRxiv, medRxiv, Europe PMC, and Semantic Scholar — so you never miss a relevant paper, wherever it was published.
Flexible delivery
Choose your day and time. Weekly, bi-weekly, or daily — configure separately for each research profile.
Team digests
Coming soonShare a lab-wide digest with your entire team. Everyone gets the same curated reading list without duplication.
Reading analytics
Coming soonTrack what you've read, saved, and cited. Understand your research activity over time.
Zotero & Notion integrations
Coming soonPush saved papers directly to your Zotero library or Notion database. One click, no copy-paste.
Multi-language support
Receive summaries in English and French. More languages coming soon.
Private & GDPR-compliant
Your research profile is encrypted. We never sell or share your data. EU-hosted infrastructure.
Why Skophos?
The name comes from the ancient Greek σκοπός — the one who keeps sight of the target. The same root behind microscope, telescope, and every instrument built to see further.
PubMed alone indexes over 1 million new papers every year. At that scale, no researcher can keep up manually. Add preprint servers, non-English publications, and adjacent fields — and staying current becomes a discipline in itself.
Skophos scans thousands of new publications each week, scores them for relevance to your exact research themes, and distills the 25 most relevant into a structured brief — every Monday morning.
From the churn — clarity.
Simple, honest pricing.
Free
For individual researchers getting started.
- Up to 10 articles per digest
- 2 research areas
- AI relevance scores
- "Why it matters" explanations
- Explorer & Collections
- Weekly, bi-weekly, or monthly delivery
- Team features
Pro
For active researchers who need full coverage.
- 25 articles per digest
- Unlimited research profiles
- Priority scoring
- Full source coverage (all databases)
- Discover — full-corpus topic explorer
- Early access to new features
- Team features
Lab
For research groups and lab teams.
- Team digests — shared reading list
- Shared workspace
- Up to 10 members
- Analytics & usage insights
- All databases covered
- API access + integrations
- Priority support
Skophos is in early access with a small group of researchers — testimonials coming soon.
Frequently asked questions.
Built for researchers, by researchers.
Skophos was born from a simple frustration: keeping up with the scientific literature shouldn't be a full-time job. We build Skophos in close collaboration with the researchers who use it — every feature is shaped by real feedback from real scientists. We're a small team. No venture capital agenda, no data reselling, no shortcuts. Just a better way to stay current.
Start today
Stop missing the papers
that matter.
Your next Monday morning could start with clarity. Set up your first personalized digest in under 5 minutes.
Free plan available. No credit card required.